We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Ion Transport Protein Linked to Brain Cancer Cell Migration and Invasion

By LabMedica International staff writers
Posted on 22 May 2012
By elaborating the molecular interactions of the ion transport protein NKCC1(Na+-K+-Cl-cotransporter 1) cancer researchers have garnered new insights into the forces that drive glioblastoma multiforme cell migration and invasion.

Glioblastoma multiforme (GBM) is an aggressive brain tumor, fatal within one year from diagnosis in most patients despite intensive treatment with surgery, radiation, and chemotherapy. More...
The migratory and microscopically invasive nature of GBM as well as its resistance to chemotherapy renders conventional therapies inadequate in its treatment.

NKCC proteins are membrane transport proteins that transport sodium (Na), potassium (K), and chloride (Cl) ions across the cell membrane. They maintain electroneutrality by moving two positively charged solutes (sodium and potassium) alongside two parts of a negatively charged solute (chloride). NKCC1 is known to regulate cell volume and intracellular chloride concentration and to play an important role in brain tumor-cell invasion.

Researchers at Johns Hopkins University (Baltimore, MD, USA) investigated (1) whether the expression of NKCC1 in human tumors correlated with tumor grade; (2) whether NKCC1 affected cell contractility and migration; (3) whether NKCC1 could have an effect on the interaction between the cells and the cells' adhesion substratum; and (4) whether a signaling mechanism involved in the regulation of NKCC1 by promigratory factors existed in GB cells.

Results published in the May 1, 2012, online edition of the journal PLoS Biology revealed that in addition to its conventional function as an ion transporter, NKCC1 also interacted with the cytoskeleton and affected brain tumor-cell migration by acting as an anchor that transduced contractile forces from the plasma membrane to the extracellular matrix en route to cell migration. Regulation of NKCC1 by a family of unconventional enzymes, the WNK kinases, was an important factor that affected the activity of NKCC1 and determined the invasive ability of brain tumor cells. NKCC1 expression correlated with in vivo glioma aggressiveness, and the transporter activity modulated migration speed and invasiveness of cells derived from various human GBs.

“The biggest challenge in brain cancer is the migration of cancer cells. We cannot control it,” said senior author Dr. Alfredo Quinones-Hinojosa, associate professor of neurosurgery and oncology at Johns Hopkins University. “If we could catch these cells before they take off into other parts of the brain, we could make malignant tumors more manageable, and improve life expectancy and quality of life. This discovery gives us hope and brings us closer to a cure.”

Related Links:
Johns Hopkins University




Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.